Imunon (IMNN) to Release Quarterly Earnings on Monday

Imunon (NASDAQ:IMNN) is expected to be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.2150) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Monday, May 11, 2026 at 11:00 AM ET.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.14. On average, analysts expect Imunon to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Imunon Trading Up 2.6%

IMNN stock traded up $0.07 on Monday, hitting $2.87. The company’s stock had a trading volume of 19,145 shares, compared to its average volume of 76,729. The firm has a 50 day moving average of $3.04 and a two-hundred day moving average of $3.57. Imunon has a 1 year low of $2.52 and a 1 year high of $41.22. The stock has a market cap of $11.27 million, a price-to-earnings ratio of -0.36 and a beta of 2.04.

Analyst Ratings Changes

IMNN has been the topic of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a research note on Tuesday, April 21st. Maxim Group set a $10.00 price objective on shares of Imunon and gave the company a “buy” rating in a research note on Friday, April 17th. Finally, reissued a “buy” rating on shares of Imunon in a research note on Wednesday, January 7th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Imunon has an average rating of “Hold” and a consensus target price of $132.50.

Hedge Funds Weigh In On Imunon

A hedge fund recently raised its stake in Imunon stock. DRW Securities LLC lifted its stake in shares of Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 58,830 shares of the company’s stock after purchasing an additional 3,803 shares during the quarter. DRW Securities LLC owned about 1.92% of Imunon worth $224,000 at the end of the most recent quarter. 4.47% of the stock is currently owned by institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.